This is the first time the China Drug Administration (CDA) provides details on how the data exclusivity applies to pre-clinical and clinical data submitted to the agency. Companies with plans to launch pharmaceutical products in China should carefully review the Draft Guidance and assess its implications.
Please see full publication below for more information.
